Original Articles Open access

Psychometric validation of the EORTC QLQ-PR25 and clinical correlates of quality of life among Albanian men with prostate cancer

Authors

Published
12 February 2026
Section
Original Articles
DOI
10.4081/hls.2026.14873

Abstract

Our aim was to assess the psychometric properties of the “EORTC QLQ-PR25” in Albania and to determine the links between disease characteristics and treatment in men with prostate cancer. A study conducted in Tirana during April 2024–December 2025 included 74 consecutive men diagnosed with prostate cancer who completed the EORTC QLQ-PR25 questionnaire (response: ≈94%). The EORTC QLQ-PR25 demonstrated excellent internal consistency across all subscales (Cronbach’s alpha range: 0.85-0.91), with very high reliability for the overall scale (α=0.94). Higher symptom burden and poorer overall quality-of-life were significantly associated with radical prostatectomy, metastatic disease, high Gleason score (9-10), and extracapsular tumour spread (all P<0.05). Patients undergoing radical prostatectomy reported the worst outcomes across all symptom domains, as well as the lowest general quality-of-life and health status scores. Seemingly, the EORTC QLQ-PR25 is a reliable and clinically valid instrument for assessing prostate cancer-specific quality-of-life among Albanian men. Also, symptom burden and quality-of-life impairment were strongly associated with disease severity and invasive treatment. Our findings support the integration of patient-reported outcomes into routine prostate cancer care in Albanian-speaking countries.

Keywords

References

  1. 1. Lin X, Zhi Y. Global epidemiological trends in prostate cancer burden: a comprehensive analysis from Global Burden of Disease Study 2021. Transl Androl Urol 2025;14:1238-52. DOI: https://doi.org/10.21037/tau-2025-103
  2. 2. Zhang W, Cao G, Wu F, et al. Global burden of prostate cancer and association with socioeconomic Status, 1990–2019: A Systematic Analysis from the Global Burden of Disease Study. J Epidemiol Glob Health 2023;13:407-21. DOI: https://doi.org/10.1007/s44197-023-00103-6
  3. 3. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229-63. DOI: https://doi.org/10.3322/caac.21834
  4. 4. Schafer EJ, Laversanne M, Sung H, et al. Recent patterns and trends in global prostate cancer incidence and mortality: an update. Eur Urol 2025;87:302-13. DOI: https://doi.org/10.1016/j.eururo.2024.11.013
  5. 5. Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013;368:436-45. DOI: https://doi.org/10.1056/NEJMoa1209978
  6. 6. Rosato R, De Luca S, Zitella A, et al. Quality of life in low-risk prostate cancer under active surveillance or following radical treatments: the START cohort study. Prostate Cancer Prostatic Dis 2025;Oct 16. doi: 10.1038/s41391-025-01032-0. Online ahead of print. DOI: https://doi.org/10.1038/s41391-025-01032-0
  7. 7. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-61. DOI: https://doi.org/10.1056/NEJMoa074311
  8. 8. Seputra KP, Daryanto B, Budaya TN, et al. Quality of life in prostate cancer patients following radical prostatectomy: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2025;26:3185-92. DOI: https://doi.org/10.31557/APJCP.2025.26.9.3185
  9. 9. Rönningås U, Holm M, Fransson P, et al. Symptoms and quality of life among men starting treatment for metastatic castration-resistant prostate cancer - a prospective multicenter study. BMC Palliat Care 2024;23:80. DOI: https://doi.org/10.1186/s12904-024-01410-w
  10. 10. Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 2010;76:1245-50. DOI: https://doi.org/10.1016/j.urology.2010.01.027
  11. 11. Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415-24. DOI: https://doi.org/10.1056/NEJMoa1606220
  12. 12. Chen RC, Basak R, Meyer AM, et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA 2017;317:1141-50. DOI: https://doi.org/10.1001/jama.2017.1652
  13. 13. Eton DT, Lepore SJ. Prostate cancer and health-related quality of life: a review of the literature. Psychooncology 2002;11:307-26. DOI: https://doi.org/10.1002/pon.572
  14. 14. Kretschmer A, van den Bergh RCN, Martini A, et al. Assessment of health-related quality of life in patients with advanced prostate cancer — current state and future perspectives. Cancers 2022;14:147. DOI: https://doi.org/10.3390/cancers14010147
  15. 15. Dasgupta P, Baade PD, Aitken JF, et al. Geographical variations in prostate cancer outcomes: a systematic review of international evidence. Front Oncol 2019;9:238. DOI: https://doi.org/10.3389/fonc.2019.00238
  16. 16. Wadhwa A, Roscoe C, Duran EA, et al. Neighborhood deprivation, race and ethnicity, and prostate cancer outcomes across california health care systems. JAMA Netw Open 2024;7:e242852. DOI: https://doi.org/10.1001/jamanetworkopen.2024.2852
  17. 17. Klein J, Hofreuter-Gätgens K, Lüdecke D, et al. Socioeconomic status and health-related quality of life among patients with prostate cancer 6 months after radical prostatectomy: a longitudinal analysis. BMJ Open 2016;6:e010968. DOI: https://doi.org/10.1136/bmjopen-2015-010968
  18. 18. Monge C, Eldridge L, Pearlman PC, et al. Global perspectives on patient-centered outcomes: advancing patient-centered cancer clinical trials globally. J Natl Cancer Inst Monogr 2025;2025:35-41. DOI: https://doi.org/10.1093/jncimonographs/lgae043
  19. 19. van Andel G, Bottomley A, Fosså SD, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 2008;44:2418-24. DOI: https://doi.org/10.1016/j.ejca.2008.07.030
  20. 20. Cella D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007;45:S3-S11. DOI: https://doi.org/10.1097/01.mlr.0000258615.42478.55
  21. 21. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76. DOI: https://doi.org/10.1093/jnci/85.5.365
  22. 22. Jurys T, Smółka M, Dzierzawa-Kloza M, et al. EORTC QLQ-C30 and EORTC QLQ-PR25 — tools for assessing the quality of life of men suffering from prostate cancer. Oncol Clin Pract 2022;18:61-7. DOI: https://doi.org/10.5603/OCP.2021.0040
  23. 23. O’Leary E, Drummond FJ, Gavin A, et al. Psychometric evaluation of the EORTC QLQ-PR25 questionnaire in assessing health-related quality of life in prostate cancer survivors: a curate’s egg. Qual Life Res 2015;24:2219-30. doi: 10.1007/s11136-015-0958-y. DOI: https://doi.org/10.1007/s11136-015-0958-y
  24. 24. Park J, Shin DW, Yun SJ, et al. Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for patients with prostate cancer - EORTC QLQ-PR25. Oncology 2013;85:299-305. DOI: https://doi.org/10.1159/000355689
  25. 25. Chang YJ, Liang WM, Wu HC, et al. Psychometric evaluation of the Taiwan Chinese version of the EORTC QLQ-PR25 for HRQOL assessment in prostate cancer patients. Health Qual Life Outcomes 2012;10:96. DOI: https://doi.org/10.1186/1477-7525-10-96
  26. 26. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976) 2000;25:3186-91. DOI: https://doi.org/10.1097/00007632-200012150-00014
  27. 27. World Health Organization. Cancer country profile 2020: Albania. Accessed: 23 January 2026. Available from: https://cdn.who.int/media/docs/default-source/country-profiles/cancer/alb_2020.pdf
  28. 28. Prifti J, Pozzo C, Najtellari E, Piccaluga PP. Cancer epidemiology in Albania: insights, challenges, and future directions. J Cancer Biomol Ther 2025;2:1-8. DOI: https://doi.org/10.62382/jcbt.v2i3.65
  29. 29. Refatllari B, Stefa J, Gega M, et al. Prevalence of physical activity and its associated sociodemographic factors among schoolchildren in Albania. Healthc Low-Resource Settings 2025;13:13370. DOI: https://doi.org/10.4081/hls.2025.13370
  30. 30. Balitsky AK, Rayner D, Britto J, et al. Patient-reported outcome measures in cancer care: an updated systematic review and meta-analysis. JAMA Netw Open 2024;7:e2424793. DOI: https://doi.org/10.1001/jamanetworkopen.2024.24793

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2026 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.